Compare · EPRX vs RVLP
EPRX vs RVLP
Side-by-side comparison of Eupraxia Pharmaceuticals Inc. (EPRX) and RVL Pharmaceuticals plc (RVLP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EPRX and RVLP operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- RVLP carries a market cap of $90.0M.
- EPRX has hit the wire 7 times in the past 4 weeks while RVLP has been quiet.
- EPRX has more recent analyst coverage (6 ratings vs 2 for RVLP).
- Company
- Eupraxia Pharmaceuticals Inc.
- RVL Pharmaceuticals plc
- Price
- $7.17-1.51%
- $0.03-29.51%
- Market cap
- -
- $90.0M
- 1M return
- +1.13%
- -
- 1Y return
- +83.61%
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 7
- 0
- Recent ratings
- 6
- 2
RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Latest EPRX
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
- William Blair initiated coverage on Eupraxia Pharmaceuticals
- SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
Latest RVLP
- RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events
- RVL Pharmaceuticals plc filed SEC Form 8-K: Other Events
- RVL Pharmaceuticals plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)
- RVL Pharmaceuticals plc filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- SEC Form 25-NSE filed by RVL Pharmaceuticals plc
- SEC Form DEF 14A filed by RVL Pharmaceuticals plc
- SEC Form PRE 14A filed by RVL Pharmaceuticals plc
- RVL Pharmaceuticals plc filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form SC 13D/A filed by RVL Pharmaceuticals plc (Amendment)